眼科贝伐单抗和曲安奈德超说明书用药的风险评估  

Risk Assessment of Off-label Use of Bevacizumab and Triamcinolone Acetonide in Ophthalmology

作　　者：徐雪姑[1] 郁引飞[1] 蔡永豪[1] 

机构地区：[1]温州医科大学附属眼视光医院药剂科,浙江温州325000

出　　处：《中国现代应用药学》2015年第5期625-629,共5页Chinese Journal of Modern Applied Pharmacy

摘　　要：目的为眼科临床贝伐单抗和曲安奈德超说明书使用提供风险评估。方法根据回顾性研究,分析贝伐单抗和曲安奈德在眼科临床上的疗效及超说明书使用可能存在的风险。结果贝伐单抗和曲安奈德短期内使用,临床疗效显著,但仍存在一定的风险。结论超说明书使用需大样本、多中心的长期随机研究,以确保患者获得的利益远大于可能的风险。眼科药品超说明书使用需围绕患者的知情同意、安全性以及管理上展开。OBJECTIVE To provide the risk assessment of off-label use of bevacizumab and triamcinolone acetonide in ophthalmology. METHODS According to the retrospective study, the clinical effects and potential risk of bevacizumab and triamcinolone acetonide in ophthalmology were analyzed. RESULTS In the short term, bevacizumab and triamcinolone acetonide had remarkable clinical effects. However, there were still some potential risks. CONCLUSION To ensure the patients receive the benefits far more than the potential risks, long-term, multicenter randomized studies should be taken out with large samples in off-label use. The off-label use in ophthalmolog should be discussed about informed consent, safety and management.

关 键 词：贝伐单抗 曲安奈德 眼科 超说明书 风险评估 

分 类 号：R969.3[医药卫生—药理学]